Contact this trialFirst, we need to learn more about you.
Anti-metabolites
TAS-102 for Neuroendocrine Carcinoma
Recruiting2 awardsPhase 2
Dallas, Texas
This trial is testing the safety and efficacy of drug TAS-102 in treating patients with extrapulmonary high-grade neuroendocrine cancer. TAS-102 has demonstrated improved survival and tolerability in patients with colorectal cancer and is currently approved by the FDA. Recently, a study showed a case of complete remission of high-grade NEC with TAS-102, so the trial is testing if TAS-102 is tolerable and effective in neuro-endocrine cancer patients.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.